Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y, Tsuji A
Research Department, Hokuriku Seiyaku Co., Ltd., Fukui, Japan.
Pharm Res. 1994 Jul;11(7):975-8. doi: 10.1023/a:1018923017954.
The transport mechanism of the H1-antagonist mepyramine at the blood-brain barrier (BBB) was studied by using primary cultured monolayers of bovine brain capillary endothelial cells (BCEC). The initial uptake of [3H]mepyramine into the BCEC showed strong temperature and concentration dependency, indicating that it involves both saturable and nonsaturable processes. Transport at the luminal membrane may be the rate-limiting process in the transcellular transport, since the values of the uptake coefficient of [3H]mepyramine at the luminal membrane (609 microliters/mg protein/min) and the transcellular permeability coefficient (488 microliters/mg protein/min) are very similar. The initial uptake of [3H]mepyramine was not affected by metabolic inhibitors, but was stimulated by preloading with the drug. Mepyramine appears to be transported into the BCEC by a carrier-mediated transport system which does not require metabolic energy, probably via a facilitated diffusion mechanism.
利用原代培养的牛脑毛细血管内皮细胞(BCEC)单层,研究了H1拮抗剂美吡拉敏在血脑屏障(BBB)处的转运机制。[3H]美吡拉敏在BCEC中的初始摄取表现出强烈的温度和浓度依赖性,表明其涉及饱和和非饱和过程。由于[3H]美吡拉敏在腔面膜处的摄取系数(609微升/毫克蛋白质/分钟)和跨细胞渗透系数(488微升/毫克蛋白质/分钟)的值非常相似,因此在腔面膜处的转运可能是跨细胞转运中的限速过程。[3H]美吡拉敏的初始摄取不受代谢抑制剂的影响,但预先加载该药物会刺激摄取。美吡拉敏似乎通过一种不依赖代谢能量的载体介导转运系统进入BCEC,可能是通过易化扩散机制。